All Blogs

Aug 10, 2022

Over the past two years, the coronavirus disease 2019 (COVID-19) pandemic has significantly impacted the global healthcare industry. The pandemic has resulted in a substantial spike in demand for at-home services. Similarly, three has been a great jump in the telemedicine industry. In particular, the need for Telep...

Aug 09, 2022

FDA Approves AstraZeneca’s Enhertu as First Targeted Therapy for HER2-low Cancer Enhertu, developed by AstraZeneca and Daiichi Sankyo, has been approved by the FDA as the first targeted therapy for HER2-low breast cancer, a new subtype of the disease previously categorized as HER2-negative. It has the potential ...

Aug 08, 2022

Dystrophic epidermolysis bullosa (DEB) is a common skin disease with a chronic history and low healing rates. Despite current management therapies, the disease has the potential to become severe and devastating for many patients over time. Dystrophic epidermolysis bullosa is classified into six types: dominant dyst...

Aug 05, 2022

Progressive multifocal leukoencephalopathy is a severe, progressive, and lethal demyelinating disease that presents in immunocompromised states. It is a rare indication, with just over 1.5K PML diagnosed incident cases in the United States, per DelveInsight analysis. It occurs in the setting of predisposing immunos...

Aug 04, 2022

iRhythm receives FDA clearance for ZEUS System for Zio watch iRhythm Technologies, a leading digital healthcare solutions firm focused on advancing cardiac care, announced that it received FDA 510(k) clearance for the ZEUS (Zio ECG Utilization Software) System for the Zio Watch. It is produced in partnership wit...

Aug 03, 2022

As per the latest findings, the prevalence of Mental Health has grown significantly over the past two-three decades. The growth has been registered in almost every country worldwide. People of any age, race, religion or economic status can get mental illnesses. It can severely impact personal and professional life ...

Aug 02, 2022

Bristol-Myers Squibb’s Opdivo and Yervoy Combo Fails in Phase III Trial Bristol-Myers Squibb has reported that their Opdivo and Yervoy checkpoint inhibitor combo failed a phase III trial as adjuvant (post-surgery) therapy for renal cell carcinoma (RCC), the most frequent type of kidney cancer. The CheckMate -914...

Aug 01, 2022

Though a rare disease, generalized myasthenia gravis (gMG) still affects around 60,000 people in the US and another 100,000 in EU-5 and Japan. As per our analysis, the total diagnosed prevalent cases of gMG were approx 116K in the 7MM in 2021. These numbers are further estimated to increase by 2032. Moreover, t...

Jul 29, 2022

Key Highlights The US approval of Jynarque added the much-needed push to the ADPKD treatment market.In the coming years, Bardoxolone methyl is expected to be an effective therapy for ADPKD treatment.The current ADPKD treatment only aims to delay the disease progression rather than completely cure the disease, wh...

Jul 28, 2022

ReCor Medical and Otsuka Medical Devices Announce Primary Endpoint Met in the RADIANCE II US Pivotal Trial of the Paradise™ System for the Treatment of Hypertension On July 26, 2022, ReCor Medical, Inc., a completely owned subsidiary of Otsuka Medical Devices Co., Ltd., with its headquarters in Palo Alto,...